Empowering Radiopharmaceutical Innovation: A Global Supply Pact Between Eckert & Ziegler and AtomVie

Empowering Radiopharmaceutical Innovation: A Global Supply Pact Between Eckert & Ziegler and AtomVie

(IN BRIEF) Eckert & Ziegler SE and AtomVie Global Radiopharma Inc. have announced a significant global supply agreement aimed at supporting AtomVie’s radiopharmaceutical manufacturing efforts. Under this agreement, Eckert & Ziegler will provide its high-grade non-carrier added Lutetium-177 chloride (Theralugand®) to assist AtomVie’s CDMO operations. This partnership is designed to support projects across all stages of development and commercialization on a global scale, ensuring that AtomVie has dependable access to a crucial component for advancing Lu-177 based radiopharmaceuticals. Both companies emphasize the flexibility of the deal, which allows them to address diverse needs and international regulatory requirements effectively. The collaboration underscores Eckert & Ziegler’s commitment to contributing to nuclear medicine advancements and AtomVie’s mission to enhance manufacturing capabilities and patient outcomes worldwide.

(PRESS RELEASE) BERLIN/ HAMILTON, ON, CA, 20-Mar-2025 — /EuropaWire/ — Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) and AtomVie Global Radiopharma Inc. (AtomVie) have entered into a landmark global supply partnership. Under this agreement, Eckert & Ziegler will supply its premium non-carrier added Lutetium-177 chloride (n.c.a. Lu-177, marketed as Theralugand®) to bolster AtomVie’s contract development and manufacturing (CDMO) efforts in the radiopharmaceutical sector.

This collaboration spans the entire spectrum of radiopharmaceutical development—from initial research stages to late-stage commercialization—and will support global initiatives. By securing consistent access to Theralugand®, AtomVie is positioned to further innovate and expand its range of Lu-177 based radiopharmaceuticals at its state-of-the-art facility. The agreement’s inherent flexibility is designed to swiftly adapt to the evolving needs of pharmaceutical partners at various phases of development and commercialization, all while meeting international regulatory standards.

Dr. Harald Hasselmann, CEO of Eckert & Ziegler SE, commented, “We are delighted to support AtomVie in advancing their global radiopharmaceutical development programs with Theralugand®. By delivering our high-quality radionuclides, we play an essential role in pushing forward therapeutic innovations in nuclear medicine.”

Bruno Paquin, CEO of AtomVie, added, “Partnering with Eckert & Ziegler marks a significant milestone in our mission to ensure that global developers of Lutetium-177 based radiopharmaceuticals receive the dependable support they require. With our new manufacturing facility opening later this year, this collaboration strengthens our capacity to provide superior, reliable manufacturing services. We eagerly anticipate working together with our partners to drive innovation and transform patient care.”

About Eckert & Ziegler
Eckert & Ziegler SE, with more than 1,000 employees, is a leading specialist in isotope-related components for nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

About AtomVie Global Radiopharma Inc.
AtomVie is a global leading CDMO for the GMP manufacturing and worldwide distribution of clinical and commercial radiopharmaceuticals. AtomVie offers the full range of scientific, technical, regulatory, quality and logistics combined with a specialized infrastructure for the development of radiopharmaceuticals from clinical studies to the commercial marketplace. AtomVie currently serves international clients conducting studies in over 25 countries worldwide. For more information, visit https://www.atomvie.com/

Contact
Eckert & Ziegler SE
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Jan Schöpflin, Marketing / Karolin Riehle, Investor Relations
jan.schoepflin@ezag.com / karolin.riehle@ezag.com
Tel.: +49 (0) 30 / 94 10 84-138; www.ezag.com

AtomVie Global Radiopharma Inc.
1280 Main St. W., NRB-A316
Hamilton, ON  L8S 4K1, Canada
Tina Chainani
tina.chainani@atomvie.com
www.atomvie.com

SOURCE: Eckert & Ziegler SE